Last Price
0.047
Today's Change
+0.002 (4.44%)
Day's Change
0.045 - 0.047
Trading Volume
11,430,139
Market Cap
349 Million
Shares Outstanding
7 Billion
Avg Volume
20,538,888
Avg Price (50 Days)
0.05
Avg Price (200 Days)
0.07
PE Ratio
-2.35
EPS
-0.02
Earnings Announcement
26-Feb-2025
Previous Close
0.04
Open
0.04
Day's Range
0.045 - 0.047
Year Range
0.043 - 0.15
Trading Volume
11,430,139
1 Day Change
4.44%
5 Day Change
9.30%
1 Month Change
-4.08%
3 Month Change
-7.84%
6 Month Change
-38.16%
Ytd Change
-57.27%
1 Year Change
-28.79%
3 Year Change
-91.97%
5 Year Change
88.00%
10 Year Change
295.22%
Max Change
-99.67%
No result.
Sector: Healthcare - Healthcare
Industry: Biotechnology
Description:
Imugene Limited, a clinical stage immuno-oncology company, develops a range of immunotherapies to activate the immune system of cancer patients to treat and eradicate tumors in Australia. Its lead product is HER-Vaxx, a HER2-positive cancer vaccine that stimulates a polyclonal antibody response against HER2/neu receptors in gastric and breast cancer. The company's HER-Vaxx is in Phase 1b/2 study for gastric cancer. It also engages in developing PD1-Vaxx, a cancer vaccine that aims to induce the body to produce polyclonal antibodies that block PD-1 signalling; and CF33, a combination of genomic sequences from various vaccinia virus strains to generate potent virus. The company has a research collaboration with Celularity Inc. to develop the combination of Imugene's CD19 oncolytic virus technology and Celularity's CD19 targeting allogeneic chimeric antigen receptor T-cell therapy, CyCART-19 for the treatment of solid tumors; and has a strategic collaboration with Eureka Therapeutics, Inc. Imugene Limited was incorporated in 1986 and is based in Sydney, Australia.